CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Introgen Therapeutics, Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Introgen Therapeutics, Inc
Suite 1850, 301 Congress Avenue
Phone: (512) 708-9310p:512 708-9310 AUSTIN, TX  78701  United States Fax: (512) 708-9311f:512 708-9311
This company ceased filing statements with the SEC on 1/30/2009.
This company is no longer actively traded on any major stock exchange.
Business Summary
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. The Company is developing product candidates to treat a range of cancers using tumor suppressors, cytokines and other targeted molecular therapies. These agents are designed to increase production of normal cancer-fighting proteins that act to overpower cancerous cells, stimulate immune activity and enhance conventional cancer therapies. The Company's products work by acting as templates for the transient in vivo production of proteins that have pharmacological properties. The resultant proteins engage disease-related molecular targets or receptors to produce specific therapeutic effects. Introgen Therapeutics' product candidate is ADVEXIN therapy.
(Source: 10-K)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/200812/31/2007YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board David G.Nance 61 11/24/2008 6/1/1993
President, Chief Executive Officer J. DavidEnloe 49 11/24/2008
Chief Financial Officer James W.Albrecht 59 4/1/1995 11/1/1994
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Gendux Molecular Limited
Gendux Pharmaceuticals Limited
Gendux, AB
4 additional Business Names available in full report.

General Information
Number of Employees: 80 (As of 3/1/2008)
Outstanding Shares: 44,142,172 (As of 11/5/2008)
Shareholders: 150
Stock Exchange: OTC
Federal Tax Id: 742704230
Fax Number: (512) 708-9311
Email Address: j.albrecht@introgen.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023